CPGR will be developing multiplex protein array-based antibody profiling assays and related bioinformatic analysis methods for the project with the ultimate aim of creating a biomarker signature that can be used for companion diagnostic purposes.
The algorithm, which was developed in collaboration with researchers in the Mathematics of Information Technology and Complex Systems groups at the University of British Columbia and Simon Fraser University, will allow Kinexus to do high-resolution mapping of an estimated 25 million kinase-substrate interactions, said a company official.
Eiger Biopharma licenses Hep C Rx IP from Stanford; TapImmune buys vaccine IP from UBC; Acetylon Pharma closes $7.25M series A to commercialize Dana-Farber, Harvard HDAC inhibitors; EMD Serono and MD Anderson ink clinical trial pact; U of Queensland's IMBcom licenses HGH receptor cell lines to Prolor Biotech
Alnylam will have the exclusive rights to all new inventions resulting from the alliance, as well as the rights to sublicense any related intellectual property. Tekmira will have the right to use new inventions with its own RNAi therapeutics.
The latest pact will focus on the use of p97 as a delivery system to transport Alzheimer's drugs across the blood-brain barrier. Last month, Bioasis and UBC inked a first research collaboration to develop and test a p97-based blood test to diagnose and monitor Alzheimer's.